Literature DB >> 16687279

PACAP--a multifacetted neuropeptide.

Jan Fahrenkrug1.   

Abstract

Pituitary adenylate cyclase activating polypeptide (PACAP) was originally isolated from ovine hypothalamus based on its ability to stimulate cAMP production in pituitary cell cultures. The peptide exists in two forms, both of which are derived from the same precursor. PACAP38 and the C-terminal truncated PACAP27 can interact with three subtypes of receptors activating adenylate cyclase and/or phospholipase C. Since its discovery, numerous studies have provided evidence that PACAP is a pleiotropic substance having a broad spectrum of biological functions; the peptide can act as a hormone, neurohormone, autocrine/paracrine substance, neurotransmitter, neuromodulator, neurotrophic factor, and immunomodulator. Two examples of the functional role of PACAP on the biological timing system are presented: 1) the transient expression of PACAP during the periovulatory period in ovarian cells, in which PACAP functions as an autocrine/paracrine inducer of progesterone secretion and subsequent luteinization; and 2) the role of PACAP as a neurotransmitter in the retinohypothalamic tract mediating photic regulation of the brain's biological clock.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16687279     DOI: 10.1080/07420520500464569

Source DB:  PubMed          Journal:  Chronobiol Int        ISSN: 0742-0528            Impact factor:   2.877


  13 in total

1.  RANTES release contributes to the protective action of PACAP38 against sodium nitroprusside in cortical neurons.

Authors:  Alma Sanchez; Debjani Tripathy; Paula Grammas
Journal:  Neuropeptides       Date:  2009-06-03       Impact factor: 3.286

2.  Granule cell survival is deficient in PAC1-/- mutant cerebellum.

Authors:  Anthony Falluel-Morel; Liana I Tascau; Katie Sokolowski; Philippe Brabet; Emanuel DiCicco-Bloom
Journal:  J Mol Neurosci       Date:  2008-04-12       Impact factor: 3.444

3.  Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) Targets Down Syndrome Candidate Region 1 (DSCR1/RCAN1) to control Neuronal Differentiation.

Authors:  Eun Hye Lee; Seon Sook Kim; Seul Lee; Kwan-Hyuck Baek; Su Ryeon Seo
Journal:  J Biol Chem       Date:  2015-07-08       Impact factor: 5.157

Review 4.  Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.

Authors:  Megan C Chapter; Caitlin M White; Angela DeRidder; Wayne Chadwick; Bronwen Martin; Stuart Maudsley
Journal:  Pharmacol Ther       Date:  2009-08-15       Impact factor: 12.310

Review 5.  VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies.

Authors:  Terry W Moody; Tetsuhide Ito; Nuramy Osefo; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2011-02       Impact factor: 3.243

Review 6.  Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Authors:  Jonathan Jia Yuan Ong; Diana Yi-Ting Wei; Peter J Goadsby
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

7.  Differentiation of PC12 cells results in enhanced VIP expression and prolonged rhythmic expression of clock genes.

Authors:  Camilla P Pretzmann; Jan Fahrenkrug; Birgitte Georg
Journal:  J Mol Neurosci       Date:  2008-09-23       Impact factor: 3.444

8.  Vasoactive neuropeptides in clinical ophthalmology: An association with autoimmune retinopathy?

Authors:  Donald R Staines; Ekua W Brenu; Sonya Marshall-Gradisnik
Journal:  Clin Ophthalmol       Date:  2009-06-02

9.  PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity.

Authors:  T S Guillot; J R Richardson; M Z Wang; Y J Li; T N Taylor; B J Ciliax; O Zachrisson; A Mercer; G W Miller
Journal:  Neuropeptides       Date:  2008-06-03       Impact factor: 3.286

10.  Effects of PACAP on the circadian changes of signaling pathways in chicken pinealocytes.

Authors:  Boglarka Racz; Gabriella Horvath; Nandor Faluhelyi; Andras D Nagy; Andrea Tamas; Peter Kiss; Ferenc Gallyas; Gabor Toth; Balazs Gaszner; Valer Csernus; Dora Reglodi
Journal:  J Mol Neurosci       Date:  2008-07-01       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.